Related Experiment Videos
British studies of aspirin and myocardial infarction
Insights
Aspirin use after myocardial infarction showed a trend toward reduced mortality in two trials, but provided no benefit during the acute phase. Further research is needed to confirm these findings for heart attack patients.
Area of Science:
- Cardiology
- Epidemiology
- Clinical Trials
Background:
- Myocardial infarction (heart attack) survivors are at increased risk of mortality.
- Aspirin is a commonly used antiplatelet medication with potential benefits in cardiovascular disease.
Purpose of the Study:
- To evaluate the efficacy of aspirin in reducing mortality in patients following myocardial infarction.
- To assess the impact of aspirin on early mortality during the acute phase of myocardial infarction.
Main Methods:
- Three randomized, controlled trials were conducted by the MRC Epidemiology Unit in Cardiff, Wales.
- Two trials followed patients for one to two years post-myocardial infarction (n=1,239 men, n=1,682 patients).
- A third trial focused on very early mortality in 2,530 patients.
Main Results:
- While not statistically significant, results from two trials suggest a potential reduction in 1-year mortality by approximately 26% and 17% after myocardial infarction.
- The third trial found no evidence of aspirin benefit in reducing mortality during the acute phase of myocardial infarction.
Conclusions:
- Aspirin may offer a potential mortality benefit for patients in the year following a myocardial infarction, though results require further investigation.
- Aspirin does not appear to be beneficial for reducing mortality during the acute phase of myocardial infarction.
Abstract:
The MRC Epidemiology Unit in Cardiff, Wales conducted three randomized, controlled trials of aspirin use in patients who had had myocardial infarction. Follow-up study for one to two years was conducted in 1,239 men after they experienced myocardial infarction and another was based on 1,682 patients followed for one year after infarction. Although the results are not statistically significant in either trial, they are consistent with a reduction of about 26 and 17 percent in the mortality rate of patients during the year after infarction. The third trial, which was concerned with a very early mortality rate, was based on a sample of 2,530 patients. This gave no evidence of benefit from aspirin use during the acute phase of infarction.